# CTIS Database - Enhanced Audit Report
_Generated: 2025-11-06 21:29:13Z_

---

## Executive Summary

- **Total Trials**: 10,147
- **Most Common Phase**: Phase I (657 trials, 6.5%)
- **Integrated Phase Trials**: 3 phase type(s)
- **Special Programs**: 3 program type(s)
- **Total People**: 196,961
- **Total Sites**: 176,549

## Trials Table Analysis

### Field: `ctNumber`

- **Fill Rate**: 100.0%
- **Unique Values**: 10,147
- **Cardinality**: 100.0%
- **Length**: min=17, max=17, avg=17.0

**Top Values**:

- 2024-515766-13-00: 1 (0.0%)
- 2023-508305-24-00: 1 (0.0%)
- 2024-511948-42-00: 1 (0.0%)
- 2023-510219-20-00: 1 (0.0%)
- 2024-518207-22-00: 1 (0.0%)

### Field: `ctStatus`

- **Fill Rate**: 0.0%
- **Unique Values**: 0
- **Cardinality**: 0.0%

### Field: `ctPublicStatusCode`

- **Fill Rate**: 100.0%
- **Unique Values**: 8
- **Cardinality**: 0.1%
- **Length**: min=1, max=1, avg=1.0

**Top Values**:

- 4: 3,362 (33.1%)
- 8: 2,092 (20.6%)
- 5: 1,955 (19.3%)
- 2: 1,876 (18.5%)
- 3: 746 (7.4%)
- 6: 109 (1.1%)
- 7: 6 (0.1%)
- 1: 1 (0.0%)

### Field: `title`

- **Fill Rate**: 100.0%
- **Unique Values**: 10,111
- **Cardinality**: 99.6%
- **Length**: min=4, max=1124, avg=185.7

**Top Values**:

- Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin: 4 (0.0%)
- Bioequivalence clinical trial of two formulations of loperamide.: 3 (0.0%)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia: 2 (0.0%)
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis: 2 (0.0%)
- A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures: 2 (0.0%)

### Field: `shortTitle`

- **Fill Rate**: 84.3%
- **Unique Values**: 8,538
- **Cardinality**: 99.8%
- **Length**: min=1, max=20, avg=10.8

**Top Values**:

- MS202329_0010: 3 (0.0%)
- 1: 3 (0.0%)
- ENHANCE: 2 (0.0%)
- RISE: 2 (0.0%)
- M23MAR: 2 (0.0%)

### Field: `sponsor`

- **Fill Rate**: 100.0%
- **Unique Values**: 2,305
- **Cardinality**: 22.7%
- **Length**: min=5, max=146, avg=28.8

**Top Values**:

- Merck Sharp & Dohme LLC: 237 (2.3%)
- Assistance Publique Hopitaux De Paris: 220 (2.2%)
- F. Hoffmann-La Roche AG: 190 (1.9%)
- AstraZeneca AB: 187 (1.8%)
- Novartis Pharma AG: 187 (1.8%)
- Boehringer Ingelheim International GmbH: 140 (1.4%)
- Pfizer Inc.: 127 (1.3%)
- Janssen - Cilag International: 109 (1.1%)
- Eli Lilly & Co.: 105 (1.0%)
- AbbVie Deutschland GmbH & Co. KG: 96 (0.9%)

### Field: `trialPhase`

- **Fill Rate**: 100.0%
- **Unique Values**: 10
- **Cardinality**: 0.1%
- **Length**: min=7, max=18, avg=9.8

**Top Values**:

- Phase III: 3,743 (36.9%)
- Phase IV: 3,009 (29.7%)
- Expanded Access: 1,041 (10.3%)
- Phase I: 657 (6.5%)
- Phase III/IV: 535 (5.3%)
- Phase I/II: 380 (3.7%)
- Non-Interventional: 328 (3.2%)
- Phase II: 247 (2.4%)
- Compassionate Use: 196 (1.9%)
- Phase II/III: 11 (0.1%)

### Field: `therapeuticAreas`

- **Fill Rate**: 100.0%
- **Unique Values**: 600
- **Cardinality**: 5.9%
- **Length**: min=23, max=593, avg=51.7

**Top Values**:

- Diseases [C] - Neoplasms [C04]: 2,980 (29.4%)
- Diseases [C] - Nervous System Diseases [C10]: 709 (7.0%)
- Diseases [C] - Cardiovascular Diseases [C14]: 597 (5.9%)
- Diseases [C] - Immune System Diseases [C20]: 566 (5.6%)
- Diseases [C] - Hemic and Lymphatic Diseases [C15]: 420 (4.1%)
- Diseases [C] - Digestive System Diseases [C06]: 415 (4.1%)
- Diseases [C] - Respiratory Tract Diseases [C08]: 343 (3.4%)
- Not possible to specify: 335 (3.3%)
- Diseases [C] - Nutritional and Metabolic Diseases [C18]: 273 (2.7%)
- Diseases [C] - Musculoskeletal Diseases [C05]: 266 (2.6%)

### Field: `countries`

- **Fill Rate**: 0.0%
- **Unique Values**: 0
- **Cardinality**: 0.0%

### Field: `decisionDate`

- **Fill Rate**: 100.0%
- **Unique Values**: 9,941
- **Cardinality**: 98.0%
- **Date Range**: 2022-07-19T00:00:00 to 2025-09-09T00:00:00 (1148 days)

### Field: `publishDate`

- **Fill Rate**: 100.0%
- **Unique Values**: 10,147
- **Cardinality**: 100.0%

### Field: `lastUpdated`

- **Fill Rate**: 100.0%
- **Unique Values**: 9,941
- **Cardinality**: 98.0%
- **Date Range**: 2022-07-19T00:00:00 to 2025-09-09T00:00:00 (1148 days)

### Phase Distribution

This shows the distribution of trials across different clinical trial phases:

**Standard Phases:**

- **Phase I**: 657 trials (6.5%)
- **Phase II**: 247 trials (2.4%)
- **Phase III**: 3,743 trials (36.9%)
- **Phase IV**: 3,009 trials (29.7%)

**Integrated Phases:**

- **Phase I/II (Integrated)**: 380 trials (3.7%)
- **Phase II/III (Integrated)**: 11 trials (0.1%)
- **Phase III/IV (Integrated)**: 535 trials (5.3%)

**Special Programs:**

- **Expanded Access**: 1,041 trials (10.3%)
- **Compassionate Use**: 196 trials (1.9%)
- **Non-Interventional**: 328 trials (3.2%)

### Trials by Decision Year

- **2022**: 195
- **2023**: 1,700
- **2024**: 6,088
- **2025**: 2,164

## Trial People Table Analysis

### People per Trial Statistics

- **Average**: 19.4
- **Median**: 9
- **Range**: 1 to 454

### Field: `role`

- **Fill Rate**: 100.0%
- **Unique Values**: 3

**Top Values**:

- Site Investigator: 176,466 (89.6%)
- Public Contact (Sponsor): 10,252 (5.2%)
- Scientific Contact (Sponsor): 10,243 (5.2%)

### Field: `email`

- **Fill Rate**: 100.0%
- **Unique Values**: 68,943
- **Valid Emails**: 99.8%

**Top Email Domains**:

- gmail.com: 17,317
- aphp.fr: 4,692
- hotmail.com: 2,838
- yahoo.com: 2,738
- salud.madrid.org: 2,108
- erasmusmc.nl: 1,634
- regionh.dk: 1,533
- abv.bg: 1,403
- chu-lyon.fr: 1,384
- sergas.es: 1,171

### Field: `phone`

- **Fill Rate**: 100.0%
- **Unique Values**: 87,756
- **Valid Phones**: 99.4%

### Field: `country`

- **Fill Rate**: 89.6%
- **Unique Values**: 34

**Top Values**:

- France: 33,051 (18.7%)
- Spain: 28,018 (15.9%)
- Germany: 24,107 (13.7%)
- Italy: 20,994 (11.9%)
- Poland: 14,948 (8.5%)
- Netherlands: 7,401 (4.2%)
- Belgium: 6,846 (3.9%)
- Czechia: 5,182 (2.9%)
- Hungary: 4,788 (2.7%)
- Bulgaria: 4,154 (2.4%)

## Trial Sites Table Analysis

### Sites per Trial Statistics

- **Average**: 17.4
- **Median**: 8
- **Range**: 1 to 452
- **Single-site Trials**: 2,656
- **Multi-site Trials**: 7,489

### Data Completeness

- **Complete Sites**: 176,549 (100.0%)

### Geographic Distribution

- **Unique Countries**: 34

**Top Countries by Site Count**:

- **France**: 32,921 (18.6%)
- **Spain**: 28,223 (16.0%)
- **Germany**: 24,115 (13.7%)
- **Italy**: 21,017 (11.9%)
- **Poland**: 14,955 (8.5%)
- **Netherlands**: 7,428 (4.2%)
- **Belgium**: 6,869 (3.9%)
- **Czechia**: 5,191 (2.9%)
- **Hungary**: 4,780 (2.7%)
- **Bulgaria**: 4,124 (2.3%)
- **Greece**: 3,766 (2.1%)
- **Denmark**: 3,375 (1.9%)
- **Romania**: 3,302 (1.9%)
- **Sweden**: 2,954 (1.7%)
- **Austria**: 2,637 (1.5%)

## Cross-Table Analysis

### Referential Integrity

- **Orphan People Records**: 0
- **Orphan Sites Records**: 0

### Data Coverage

- **Trials Without Sites**: 2 (0.0%)
- **Trials Without People**: 0 (0.0%)

### Combined Statistics

- **Average Sites per Trial**: 17.4
- **Average People per Trial**: 19.4
- **Max Sites (Single Trial)**: 452
- **Max People (Single Trial)**: 454

---

_Report generated by CTIS Enhanced Audit Tool_
